Class Action Alert for Agenus Inc. Shareholders
Attention investors of Agenus Inc. (NASDAQ: AGEN)! There is a significant class action notice that you shouldn’t overlook. The Gross Law Firm is reaching out to shareholders who may have incurred losses during the class period outlined below.
Why Shareholders Should Act
Shareholders who bought shares during this critical period are encouraged to connect with the Gross Law Firm. They aim to provide assistance regarding the lead plaintiff appointment. Please note that registering does not require you to take on the role of a lead plaintiff to be part of any possible recovery.
Important Class Period Information
The class period for this action spans from January 23, 2023, to July 17, 2024. If you were involved in this timeframe, it is crucial to act quickly and secure your position.
Allegations Against Agenus Inc.
The pending complaint centers around allegations that the company provided materially false or misleading information. According to the claims, the efficacy of their immuno-oncology drugs, botensilimab and balstilimab, was overstated. Concerns include that the clinical results and overall market potential for these therapies were not accurately represented by the company, leading to investor misinformation.
Be Aware of Key Deadlines
Mark your calendars as the deadline to take action is approaching quickly on November 5, 2024. Shareholders aiming to participate in this class action should not delay their registration. It's essential to ensure your representation and monitor your standing in this case.
Steps to Take as a Shareholder
Once you complete your registration as a shareholder involved in this matter, you will gain access to a portfolio monitoring system. This feature allows you to receive status updates throughout the lifecycle of the ongoing case. Remember, participating in this case at any level involves no financial cost or obligation for you.
The Commitment of The Gross Law Firm
The Gross Law Firm is known for its commitment to defending investors' rights against deceitful practices and fraudulent activities. Their expertise focuses on ensuring responsible business conduct and helping clients recover losses caused by misleading claims from companies.
Contact Information
For those who wish to learn more about this situation, The Gross Law Firm can be contacted directly with the following details:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the class period for the Agenus Inc. class action?
The class period for the action is from January 23, 2023, to July 17, 2024.
How can I register for the class action?
Shareholders can register by contacting The Gross Law Firm for assistance.
Is there a cost to participate in the class action?
No, there is no cost or obligation for shareholders to participate in this class action.
What are the allegations against Agenus Inc.?
The allegations center around misleading information regarding the efficacy of their immuno-oncology products.
How does the lead plaintiff process work?
Shareholders can register to be lead plaintiffs, but it is not a requirement to partake in the class action recovery process.
